The effect of dydrogesterone and various forms of progesterone in support of artificial reproduction techniques

Comparison of oral dydrogesterone versus other forms of progesterone as a luteal cycles support in assisted reproductive technology (ART)

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016010825902N1

Enrollment

159

Registered

2016-01-22

Start date

2015-10-18

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Artificial fertilization. Complications of attempted introduction of fertilized ovum following in vitro fertilization

Interventions

Intervention 1: Intervention group 1: Prescription oral dose of 10 mg of dydrogesterone, Three times a day, since ovum retrieval until the twelfth week of pregnancy. Intervention 2: Intervention group

Treatment - Drugs

Intervention group 1: Prescription oral dose of 10 mg of dydrogesterone, Three times a day, since ovum retrieval until the twelfth week of pregnancy.

Intervention group 2: Prescription 400 mg of progesterone vaginal suppository, twice a day, since ovum retrieval until the twelfth week of pregnancy.

Control group: Prescription 50 mg of intramuscular progesterone, twice a day, since ovum retrieval until the twelfth week of pregnancy

Eligibility

Sex/Gender

Female

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria: Patients candidate for in vitro fertilization (IVF) or intracytoplasmic cytoplasmic sperm injection (ICSI); Having a normal uterus. Exclusion Criteria: Abnormal uterus such as submucosal myoma and endometrial adhesions; Sensitivity to progesterone; Lack of fertilization; Having a systemic disease.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pregnancy. Timepoint: Once a week after embryo transfer into the patient. Method of measurement: The blood hCG test.;Preterm delivery. Timepoint: Every two weeks from the twentieth week of pregnancy. Method of measurement: Patient appointments and record uterine contractions.;Amount of live birth. Timepoint: Every two weeks from twenty-eighth week of pregnancy. Method of measurement: Patient appointments and record baby's birth.;Grade and the number of transferred embryo cells. Timepoint: Immediately before embryo transfer into the patient. Method of measurement: By using microscope.	—

Measure

Time frame

Pregnancy. Timepoint: Once a week after embryo transfer into the patient. Method of measurement: The blood hCG test.;Preterm delivery. Timepoint: Every two weeks from the twentieth week of pregnancy. Method of measurement: Patient appointments and record uterine contractions.;Amount of live birth. Timepoint: Every two weeks from twenty-eighth week of pregnancy. Method of measurement: Patient appointments and record baby's birth.;Grade and the number of transferred embryo cells. Timepoint: Immediately before embryo transfer into the patient. Method of measurement: By using microscope.

—

Secondary

Measure	Time frame
Perineal irritation caused by progesterone vaginal suppository. Timepoint: Every two weeks during treatment period. Method of measurement: Verbal questionnaire and the patient's response.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Sadat Ejtahed

Ahvaz Jundishapur University of Medical Sciences

dr.maryamejtahed@gmail.com+98 61 3222 2922

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026